Stem cells

Nkarta Establishes New Combined NK Cell Therapy Manufacturing Facility / Company Headquarters

Retrieved on: 
Wednesday, July 14, 2021
Branches of biology, Biology, Medical specialties, Immune system, Lymphocytes, Biotechnology, Stem cells, Cell biology, Natural killer cell, Cell therapy, T cell, Chimeric antigen receptor T cell

The manufacturing center will be custom designed to complement Nkartas state-of-the-art technology platform and optimize the production of its multiple off-the-shelf NK cell therapy investigational products.

Key Points: 
  • The manufacturing center will be custom designed to complement Nkartas state-of-the-art technology platform and optimize the production of its multiple off-the-shelf NK cell therapy investigational products.
  • At full capacity, the manufacturing center is expected to have the flexibility to produce commercial supply of multiple cell therapy products.
  • All of Nkartas NK current cell therapy candidates are also engineered with a membrane-bound IL15, a proprietary version of a cytokine known for activating NK cell growth, to enhance the persistence and activity of the NK cells.
  • Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for cancer patients.

TransCode Therapeutics, Inc. Announces Closing of Initial Public Offering, Including Full Exercise of Underwriters' Over-allotment Option

Retrieved on: 
Tuesday, July 13, 2021
Biotechnology, Health, Oncology, Stem cells, Finance, Financial markets, Stock market, Economy of New York City, NASDAQ, ThinkEquity, Security, Service companies

The shares sold in the offering began trading on July 9, 2021 on the Nasdaq Capital Market under the symbol RNAZ.

Key Points: 
  • The shares sold in the offering began trading on July 9, 2021 on the Nasdaq Capital Market under the symbol RNAZ.
  • Proceeds will also be used for strategic expansion of TransCodes drug candidate portfolio and for working capital and general corporate purposes.
  • ThinkEquity, a division of Fordham Financial Management, Inc., acted as sole book-running manager for the offering.
  • 333-253599) relating to the shares was filed with the Securities and Exchange Commission (SEC) and became effective on July 8, 2021.

Athersys to Host Second Quarter Financial Results Call

Retrieved on: 
Tuesday, July 13, 2021
Biotechnology, Health, Stem cells, Pharmaceutical, Clinical trials

Once registered, you will receive an email containing the toll-free number, a direct entry passcode and a registrant ID.

Key Points: 
  • Once registered, you will receive an email containing the toll-free number, a direct entry passcode and a registrant ID.
  • A replay of the event will be available on the webcast link at www.athersys.com under the investors' section approximately two hours after the call has ended.
  • Athersys is a biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life.
  • Athersys has forged strategic partnerships and a broad network of collaborations to further advance the MultiStem cell therapy toward commercialization.

Vyant Bio Announces Issuance of Key Patent for High-Throughput Optical Assay of Human Mixed Cell Population Spheroids

Retrieved on: 
Tuesday, July 13, 2021
Life sciences, Natural sciences, Intellectual property law, Biotechnology, Stem cells, Assay, Biochemistry, Titration, United States Patent and Trademark Office, Patent, Drug discovery, Induced pluripotent stem cell

11054408, titled High Throughput Optical Assay of Human Mixed Cell Population Spheroids by the United States Patent and Trademark Office (USPTO).

Key Points: 
  • 11054408, titled High Throughput Optical Assay of Human Mixed Cell Population Spheroids by the United States Patent and Trademark Office (USPTO).
  • The issuance of the 11054408 patent is the third patent granted to StemoniX: additional applications are currently pending worldwide.
  • Human iPSCs offer many advantages over recombinant cell lines or primary rodent cells for use in drug screening.
  • Vyant Bio, Inc. (Vyant Bio, the Company) (Nasdaq: VYNT) is emerging as an advanced biotechnology drug discovery company.

Cell Science Systems Reports Newly Discovered Cause of Delayed Food Allergies (Sensitivities)

Retrieved on: 
Tuesday, July 13, 2021
Other Consumer, Medical devices, Infectious diseases, Women, Seniors, Genetics, Fitness & Nutrition, MEN, Other Technology, Clinical trials, Family, Biotechnology, Alternative medicine, Hardware, Consumer, Health, Science, Other Science, Technology, Research, Diabetes, Nanotechnology, Stem cells, Practice Management, Managed care, General Health, Teens, Parenting, Children, Other Health, Oncology, Medical specialties, Immunology, Clinical medicine, Food allergies, Allergology, Immune system, Respiratory diseases, Allergy, Immunoglobulin E, Wheat allergy, Allergies in cats

However, researchers from University Leipzig (Germany) and Georgetown University together with Cell Science Systems may have found the key to understanding the most difficult type of food allergies know as delayed food allergies or sensitivities.

Key Points: 
  • However, researchers from University Leipzig (Germany) and Georgetown University together with Cell Science Systems may have found the key to understanding the most difficult type of food allergies know as delayed food allergies or sensitivities.
  • Delayed food allergies or sensitivities (also referred to as non-IgE mediated food allergies) are difficult to identify because symptoms are less acute and may take hours or even days to develop.
  • Hence, there is a great need for a test that can accurately and cost-effectively identify food and food product triggers of delayed food allergies.
  • ), are responsible for delayed food allergies and release more DNA, and other associated proteins, when exposed to an ALCAT Test positive food.

AIVITA Biomedical and University of California at Irvine Collaborators Validate 3D Printed Bioreactor for Retinal Organoid Creation

Retrieved on: 
Tuesday, July 13, 2021
Branches of biology, Stem cells, Biology, Organoid, Tissue engineering, Retina, Cerebral organoid

In the study, researchers from AIVITA Biomedical and the University of California at Irvine designed and demonstrated a bioreactor for nearly labor-free retinal organoid maintenance.

Key Points: 
  • In the study, researchers from AIVITA Biomedical and the University of California at Irvine designed and demonstrated a bioreactor for nearly labor-free retinal organoid maintenance.
  • Retinal degeneration is a leading cause of vision impairment and blindness worldwide, with limited treatment options available for advanced stages of the disease.
  • In this study, researchers designed a shear stress-free micro-millifluidic bioreactor for nearly labor-free retinal organoid maintenance.
  • The result was the successful creation of bioreactor-cultured retinal organoids with cell types and morphology comparable to static cultured retinal organoids and exhibiting similar retinal gene expression levels.

Huize Partners with Sungrow to Launch Immune Cell Cryopreservation as a New Value-added Service

Retrieved on: 
Tuesday, July 13, 2021
Branches of biology, Immunology, Emerging technologies, Immune system, Cryopreservation, Biology, T cell, Tissue plasminogen activator, Stem cells

The immune cell cryopreservation technology is supported by BGI Cell, and refers to the use of advanced biotechnology to extract immune cells from a healthy human body to be preserved attemperaturesbelow 196C.

Key Points: 
  • The immune cell cryopreservation technology is supported by BGI Cell, and refers to the use of advanced biotechnology to extract immune cells from a healthy human body to be preserved attemperaturesbelow 196C.
  • These dormant cells can be reactivated in the future and are valuable for anti-aging, tissue regeneration, immune regulation, and other disease treatments.
  • Huize Holding Limited is a leading digital insurance product and service platform for new generation consumers in China.
  • Sungrow is an insurance data and technology enabled third-party administrator (TPA) service provider serving the middle-aged and elderly health insurance market.

Caribou Biosciences Announces Dosing of First Patient in Phase 1 Clinical Trial Evaluating CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

Retrieved on: 
Monday, July 12, 2021
Health, Genetics, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Branches of biology, Biology, Life sciences, Stem cells, Cell biology, Biotechnology, Rachel Haurwitz, Cancer immunotherapy, T cells, Cell therapy, Chimeric antigen receptor T cell, CB-010, the Phase 1, Dose Escalation Study of CB-010 (ANTLER Study, NCT04637763), Caribou’s Novel Next-Generation CRISPR Platform, Caribou Biosciences, Inc., CB-010, THE PHASE 1, DOSE ESCALATION STUDY OF CB-010 (ANTLER STUDY, NCT04637763), CARIBOU’S NOVEL NEXT-GENERATION CRISPR PLATFORM, CARIBOU BIOSCIENCES, INC.

Advancing our first allogeneic CAR-T cell therapy into the clinic represents a major milestone for Caribou, said Rachel Haurwitz, Ph.D., Caribous president and chief executive officer.

Key Points: 
  • Advancing our first allogeneic CAR-T cell therapy into the clinic represents a major milestone for Caribou, said Rachel Haurwitz, Ph.D., Caribous president and chief executive officer.
  • We believe that improving cell persistence is the key to unlocking the full potential of these therapies.
  • This allows us to create sophisticated allogeneic cell therapies with enhanced characteristics to potentially improve their effectiveness and durability of antitumor activity compared to other allogeneic cell therapies.
  • Caribou Biosciences and the Caribou logo are registered trademarks of Caribou Biosciences, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210712005106/en/

INmune Bio, Inc. Announces First Patient Treated with NK cell priming “pseudokine” INKmune in High-Risk Myelodysplastic Syndrome (MDS)

Retrieved on: 
Monday, July 12, 2021
Branches of biology, Biology, Medical specialties, Stem cells, Biotechnology, Immune system, Lymphocytes, Natural killer cell, Hematopoietic stem cell, Myelodysplastic syndrome, Clonal hypereosinophilia

MDS is a serious hematopoietic stem cell disorder in which patients have functionally defective NK cells and the level of dysfunction is predictive of overall survival.

Key Points: 
  • MDS is a serious hematopoietic stem cell disorder in which patients have functionally defective NK cells and the level of dysfunction is predictive of overall survival.
  • Current treatments, including chemotherapy and bone marrow/stem cell transplantation, have varying degrees of success, and there is no known cure for MDS.
  • In the lab we have shown that INKmune binds to multiple NK receptors and initiates the activation of over 3000 genes associated with function, trafficking, proliferation and survival.
  • No single cytokine in our hands has such broad, physiological effects, which has inspired us to refer to INKmune as a pseudokine.

Global Cell and Gene Therapy Market Report 2021: Opportunities, Strategies, COVID-19 Impacts, Growth and Changes to 2030 - ResearchAndMarkets.com

Retrieved on: 
Monday, July 12, 2021
Genetics, Health, Oncology, Stem cells, Branches of biology, Life sciences, Biology, Biotechnology, Emerging technologies, Molecular biology, Stem cells, Medical genetics, Therapy, Gene therapy, Cancer, Cell therapy

The "Cell and Gene Therapy market Global Market Opportunities and Strategies to 2030: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cell and Gene Therapy market Global Market Opportunities and Strategies to 2030: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.
  • Going forward increasing prevalence of cancer and chronic diseases, rising geriatric population, rising geriatric population, rising focus on cell and gene therapy, and rise in healthcare expenditure will drive the growth in the cell and gene therapy market.
  • The cell and gene therapy market is segmented by product into cell therapy, and gene therapy.
  • The gene therapy market was the largest segment of the cell and gene therapy market segmented by product, accounting for 72.4% of the total in 2020.